273 related articles for article (PubMed ID: 20049173)
1. Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.
Culjkovic B; Borden KL
J Oncol; 2009; 2009():981679. PubMed ID: 20049173
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
Assouline S; Culjkovic B; Cocolakis E; Rousseau C; Beslu N; Amri A; Caplan S; Leber B; Roy DC; Miller WH; Borden KL
Blood; 2009 Jul; 114(2):257-60. PubMed ID: 19433856
[TBL] [Abstract][Full Text] [Related]
3. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.
Pettersson F; Del Rincon SV; Miller WH
Expert Opin Ther Targets; 2014 Sep; 18(9):1035-48. PubMed ID: 25004955
[TBL] [Abstract][Full Text] [Related]
4. The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.
Osborne MJ; Borden KL
Immunol Rev; 2015 Jan; 263(1):210-23. PubMed ID: 25510279
[TBL] [Abstract][Full Text] [Related]
5. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
Xu M; Tao Z; Wang S; Jiang Y; Qu M
Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
[TBL] [Abstract][Full Text] [Related]
6. Analysis of eIF4E and 4EBP1 mRNAs in head and neck cancer.
Sunavala-Dossabhoy G; Palaniyandi S; Clark C; Nathan CO; Abreo FW; Caldito G
Laryngoscope; 2011 Oct; 121(10):2136-41. PubMed ID: 21898433
[TBL] [Abstract][Full Text] [Related]
7. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line.
DeFatta RJ; Nathan CO; De Benedetti A
Laryngoscope; 2000 Jun; 110(6):928-33. PubMed ID: 10852506
[TBL] [Abstract][Full Text] [Related]
8. eIF4E expression in tumors: its possible role in progression of malignancies.
De Benedetti A; Harris AL
Int J Biochem Cell Biol; 1999 Jan; 31(1):59-72. PubMed ID: 10216944
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
[TBL] [Abstract][Full Text] [Related]
10. Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor.
Sorrells DL; Meschonat C; Black D; Li BD
J Surg Res; 1999 Jul; 85(1):37-42. PubMed ID: 10383835
[TBL] [Abstract][Full Text] [Related]
11. Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?
Borden KL; Culjkovic-Kraljacic B
Leuk Lymphoma; 2010 Oct; 51(10):1805-15. PubMed ID: 20629523
[TBL] [Abstract][Full Text] [Related]
12. Serotonin increases phosphorylation of synaptic 4EBP through TOR, but eukaryotic initiation factor 4E levels do not limit somatic cap-dependent translation in aplysia neurons.
Carroll M; Dyer J; Sossin WS
Mol Cell Biol; 2006 Nov; 26(22):8586-98. PubMed ID: 16982686
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E.
Ko SY; Guo H; Barengo N; Naora H
Clin Cancer Res; 2009 Jul; 15(13):4336-47. PubMed ID: 19458052
[TBL] [Abstract][Full Text] [Related]
14. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap.
Kentsis A; Topisirovic I; Culjkovic B; Shao L; Borden KL
Proc Natl Acad Sci U S A; 2004 Dec; 101(52):18105-10. PubMed ID: 15601771
[TBL] [Abstract][Full Text] [Related]
15. Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers.
Sorrells DL; Ghali GE; De Benedetti A; Nathan CO; Li BD
J Oral Maxillofac Surg; 1999 Mar; 57(3):294-9. PubMed ID: 10077200
[TBL] [Abstract][Full Text] [Related]
16. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer.
Nathan CO; Franklin S; Abreo FW; Nassar R; De Benedetti A; Glass J
J Clin Oncol; 1999 Sep; 17(9):2909-14. PubMed ID: 10561370
[TBL] [Abstract][Full Text] [Related]
17. Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E.
Culjkovic B; Topisirovic I; Borden KL
Cell Cycle; 2007 Jan; 6(1):65-9. PubMed ID: 17245113
[TBL] [Abstract][Full Text] [Related]
18. Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation.
Hu Z; Zhen L; Li Q; Han Q; Hua Q
Biochem Biophys Res Commun; 2019 Jun; 513(4):862-868. PubMed ID: 31000196
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.
Cao J; Sun X; Zhang X; Chen D
Clin Transl Oncol; 2018 Jun; 20(6):761-767. PubMed ID: 29086249
[TBL] [Abstract][Full Text] [Related]
20. Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.
Jin J; Xiang W; Wu S; Wang M; Xiao M; Deng A
Biochem Biophys Res Commun; 2019 Mar; 510(4):580-586. PubMed ID: 30739792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
